CL2020000169A1 - Compuestos macrocíclicos y usos de los mismos. - Google Patents

Compuestos macrocíclicos y usos de los mismos.

Info

Publication number
CL2020000169A1
CL2020000169A1 CL2020000169A CL2020000169A CL2020000169A1 CL 2020000169 A1 CL2020000169 A1 CL 2020000169A1 CL 2020000169 A CL2020000169 A CL 2020000169A CL 2020000169 A CL2020000169 A CL 2020000169A CL 2020000169 A1 CL2020000169 A1 CL 2020000169A1
Authority
CL
Chile
Prior art keywords
compounds
macrocyclic compounds
csf1r
met
methods
Prior art date
Application number
CL2020000169A
Other languages
English (en)
Spanish (es)
Inventor
Dayong Zhai
Jingrong Jean Cui
Evan W Rogers
Jane Ung
Jeffrey Whitten
Wei Deng
Xin Zhang
Zhongdong Huang
Jing Liu
Han Zhang
Original Assignee
Turning Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65039935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2020000169(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Turning Point Therapeutics Inc filed Critical Turning Point Therapeutics Inc
Publication of CL2020000169A1 publication Critical patent/CL2020000169A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CL2020000169A 2017-07-28 2020-01-20 Compuestos macrocíclicos y usos de los mismos. CL2020000169A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762538193P 2017-07-28 2017-07-28
US201862700990P 2018-07-20 2018-07-20

Publications (1)

Publication Number Publication Date
CL2020000169A1 true CL2020000169A1 (es) 2020-08-14

Family

ID=65039935

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000169A CL2020000169A1 (es) 2017-07-28 2020-01-20 Compuestos macrocíclicos y usos de los mismos.

Country Status (29)

Country Link
US (4) US11286264B2 (OSRAM)
EP (1) EP3658148B1 (OSRAM)
JP (2) JP7224334B2 (OSRAM)
KR (1) KR102645316B1 (OSRAM)
CN (1) CN111182903A (OSRAM)
AU (1) AU2018306328B2 (OSRAM)
BR (1) BR112020001695A2 (OSRAM)
CA (1) CA3069232A1 (OSRAM)
CL (1) CL2020000169A1 (OSRAM)
CO (1) CO2020000633A2 (OSRAM)
DK (1) DK3658148T3 (OSRAM)
ES (1) ES2986593T3 (OSRAM)
FI (1) FI3658148T3 (OSRAM)
HR (1) HRP20241197T1 (OSRAM)
IL (1) IL271964B2 (OSRAM)
LT (1) LT3658148T (OSRAM)
MY (1) MY201925A (OSRAM)
PE (1) PE20200700A1 (OSRAM)
PH (1) PH12020500033A1 (OSRAM)
PL (1) PL3658148T3 (OSRAM)
PT (1) PT3658148T (OSRAM)
RS (1) RS65884B1 (OSRAM)
SA (1) SA520411108B1 (OSRAM)
SG (1) SG11202000356VA (OSRAM)
SI (1) SI3658148T1 (OSRAM)
SM (1) SMT202400343T1 (OSRAM)
TW (1) TWI818917B (OSRAM)
UA (1) UA126158C2 (OSRAM)
WO (1) WO2019023417A1 (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015112806A2 (en) 2014-01-24 2015-07-30 Tp Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
ES2864839T3 (es) 2015-07-02 2021-10-14 Turning Point Therapeutics Inc Macrociclos de diarilo quirales como moduladores de proteína quinasas
MX383823B (es) 2015-07-21 2025-03-14 Turning Point Therapeutics Inc Macrociclos de diarilo quirales y usos de los mismo.
CN109715165A (zh) 2016-07-28 2019-05-03 Tp生物医药公司 巨环激酶抑制剂
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
MY201925A (en) 2017-07-28 2024-03-23 Turning Point Therapeutics Inc Macrocyclic compounds and uses thereof
CN109516999B (zh) * 2017-11-01 2021-08-17 郑州泰基鸿诺医药股份有限公司 用作蛋白质激酶调节剂的化合物及其应用
JP7194188B2 (ja) 2017-12-19 2022-12-21 ターニング・ポイント・セラピューティクス・インコーポレイテッド 疾患を治療するための大環状化合物
CN111902417B (zh) 2018-04-25 2023-07-28 北京普祺医药科技股份有限公司 一种二芳基巨环化合物、药物组合物以及其用途
KR102850357B1 (ko) 2018-10-22 2025-08-27 알루미스 인크. Tyk2 억제제 및 이의 용도
AU2020239026B2 (en) * 2019-03-11 2025-10-09 Alumis Inc. TYK2 inhibitors and uses thereof
WO2020233645A1 (zh) 2019-05-21 2020-11-26 浙江海正药业股份有限公司 大环类衍生物、及其制备方法和用途
CN114423762B (zh) * 2019-09-30 2024-03-29 浙江海正药业股份有限公司 大环类衍生物及其制备方法和用途
CN115397514A (zh) * 2020-03-02 2022-11-25 特普医药公司 大环化合物的治疗用途
US20230219978A1 (en) * 2020-06-04 2023-07-13 Scinnohub Pharmaceutical Co., Ltd Compound having macrocyclic structure and use thereof
CN111620881B (zh) * 2020-07-08 2023-03-31 浙江合聚生物医药有限公司 拉罗替尼衍生物及其制备方法和应用
CN116635076A (zh) * 2020-12-17 2023-08-22 荣山医药股份有限公司 大环化合物及其用途
CN114685532A (zh) * 2020-12-31 2022-07-01 正大天晴药业集团股份有限公司 大环类化合物及其医药用途
WO2022171139A1 (zh) * 2021-02-10 2022-08-18 北京国鸿生物医药科技有限公司 一种巨环化合物、药物组合物以及其用途
WO2022246092A1 (en) * 2021-05-21 2022-11-24 Blossomhill Therapeutics, Inc. Macrocyclic compounds for treating disease
CN116063326B (zh) * 2021-11-02 2025-08-05 赛诺哈勃药业（成都）有限公司 作为蛋白激酶调节剂的含氨基大环化合物
US12168640B2 (en) 2021-11-16 2024-12-17 ProDeg, LLC USP9X inhibitors
EP4433462A4 (en) * 2021-11-16 2025-07-16 Prodeg Llc USP9X INHIBITORS
IL313670A (en) 2021-12-30 2024-08-01 Biomea Fusion Inc Pyrazine compounds as inhibitors of FLT3

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021608A1 (en) 1993-03-25 1994-09-29 The Upjohn Company Indoletetralins having dopaminergic activity
AU687909B2 (en) 1993-12-07 1998-03-05 Eli Lilly And Company Protein kinase C inhibitors
GB9800569D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
US7115651B2 (en) 2000-08-25 2006-10-03 Sloan-Kettering Institute For Cancer Research Macrocycles and uses thereof
ATE301661T1 (de) 2000-12-08 2005-08-15 Ortho Mcneil Pharm Inc Makroheterocyclische verbindungen als kinase inhibitoren
JP5749645B2 (ja) 2008-09-08 2015-07-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ タンパク質キナーゼ阻害剤としての大環状ピリミジン
EP2350075B1 (en) 2008-09-22 2014-03-05 Array Biopharma, Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
KR101853026B1 (ko) 2008-10-22 2018-04-27 어레이 바이오파마 인크. ＴＲＫ 키나아제 억제제로서 치환된 피라졸로［１,５­ａ］ 피리미딘 화합물
EP2348860B1 (en) 2008-10-31 2015-05-27 Genentech, Inc. Pyrazolopyrimidine jak inhibitor compounds and methods
ES2446720T3 (es) 2009-10-13 2014-03-10 Elanco Animal Health Ireland Limited Inhibidores de la integrasa macrocíclica
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
CN105693720B (zh) 2010-05-20 2019-01-18 阵列生物制药公司 作为trk激酶抑制剂的大环化合物
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
EP2508607A1 (en) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
WO2012168986A1 (ja) 2011-06-10 2012-12-13 株式会社メンテック 汚染防止剤組成物
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
EP2744507A4 (en) 2011-08-19 2015-01-28 Merck Sharp & Dohme CRYSTAL FORMS OF AN HCV PROTEASE HEMMER
US9090630B2 (en) 2011-09-30 2015-07-28 Oncodesign S.A. Macrocyclic FLT3 kinase inhibitors
ES2621220T3 (es) 2012-03-06 2017-07-03 Pfizer Inc. Derivados macrocíclicos para el tratamiento de enfermedades proliferativas
EP2822559B1 (en) 2012-03-09 2018-05-02 Lexicon Pharmaceuticals, Inc. Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and uses thereof
MX381849B (es) 2012-03-09 2025-03-13 Lexicon Pharmaceuticals Inc Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y métodos para su uso.
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
WO2015073267A1 (en) 2013-11-15 2015-05-21 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
WO2015112806A2 (en) * 2014-01-24 2015-07-30 Tp Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
TWI736134B (zh) * 2014-09-11 2021-08-11 美商特普醫葯公司 作為蛋白質激酶之調節劑的二芳基巨環
ES2864839T3 (es) 2015-07-02 2021-10-14 Turning Point Therapeutics Inc Macrociclos de diarilo quirales como moduladores de proteína quinasas
ES2979111T3 (es) 2015-07-06 2024-09-24 Turning Point Therapeutics Inc Polimorfo de macrociclo de diarilo
MX383823B (es) 2015-07-21 2025-03-14 Turning Point Therapeutics Inc Macrociclos de diarilo quirales y usos de los mismo.
US10065963B2 (en) * 2015-11-06 2018-09-04 Incyte Corporation Heterocyclic compounds as PI3K-γ inhibitors
CN109715165A (zh) * 2016-07-28 2019-05-03 Tp生物医药公司 巨环激酶抑制剂
EP3533796B1 (en) * 2016-10-28 2021-09-29 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
MY201925A (en) * 2017-07-28 2024-03-23 Turning Point Therapeutics Inc Macrocyclic compounds and uses thereof
WO2019120267A1 (zh) 2017-12-22 2019-06-27 成都先导药物开发股份有限公司 一种咪唑并[1,2-b]哒嗪大环类激酶抑制剂
AU2019254979B2 (en) 2018-04-18 2021-08-12 Hitgen Inc. Macrocyclic kinase inhibitor

Also Published As

Publication number Publication date
US11155563B2 (en) 2021-10-26
JP2023065403A (ja) 2023-05-12
TWI818917B (zh) 2023-10-21
IL271964B2 (en) 2024-12-01
US20240391935A1 (en) 2024-11-28
RS65884B1 (sr) 2024-09-30
HRP20241197T1 (hr) 2024-11-22
SI3658148T1 (sl) 2024-10-30
JP2020528907A (ja) 2020-10-01
TW201920198A (zh) 2019-06-01
IL271964A (en) 2020-02-27
PT3658148T (pt) 2024-08-26
PE20200700A1 (es) 2020-06-23
WO2019023417A1 (en) 2019-01-31
CA3069232A1 (en) 2019-01-31
UA126158C2 (uk) 2022-08-25
US20220324879A1 (en) 2022-10-13
FI3658148T3 (fi) 2024-09-20
EP3658148A1 (en) 2020-06-03
KR102645316B1 (ko) 2024-03-07
SG11202000356VA (en) 2020-02-27
BR112020001695A2 (pt) 2020-07-21
PH12020500033A1 (en) 2020-09-28
US11286264B2 (en) 2022-03-29
AU2018306328A1 (en) 2020-01-16
CO2020000633A2 (es) 2020-01-31
JP7224334B2 (ja) 2023-02-17
US20210214373A1 (en) 2021-07-15
EP3658148A4 (en) 2021-04-28
DK3658148T3 (da) 2024-10-07
PL3658148T3 (pl) 2024-10-07
JP7554300B2 (ja) 2024-09-19
MY201925A (en) 2024-03-23
US20200157119A1 (en) 2020-05-21
KR20200034998A (ko) 2020-04-01
SMT202400343T1 (it) 2024-11-15
AU2018306328B2 (en) 2023-03-09
LT3658148T (lt) 2024-09-10
US11981684B2 (en) 2024-05-14
IL271964B1 (en) 2024-08-01
SA520411108B1 (ar) 2024-03-03
ES2986593T3 (es) 2024-11-12
CN111182903A (zh) 2020-05-19
EP3658148B1 (en) 2024-07-10

Similar Documents

Publication Publication Date Title
CL2020000169A1 (es) Compuestos macrocíclicos y usos de los mismos.
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
CL2019000820A1 (es) Compuestos, composiciones y sus usos para inhibir la actividad arginasa. (divisional solicitud 201801134)
MX2018016273A (es) Compuestos heterociclicos como inmunomoduladores.
CO2019007839A2 (es) Composiciones y métodos para inhibir la acción de la arginasa
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
MX2020001360A (es) Macrociclos de diarilo como moduladores de la proteina quinasa.
CU20160162A7 (es) Derivados de pirrolidina-2,5-diona,para usar como inhibidores ido1 y composiciones farmacéuticas que los contienen
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CL2017001046A1 (es) Inhibidoes del bromodominio
MX394062B (es) Métodos para el tratamiento del cáncer ovárico.
MX2018005528A (es) Inhibidores de ret.
SV2016005180A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
MX2016002137A (es) Ciertas entidades quimicas, composiciones y metodos.
CR20150316A (es) Compuestos y sus métodos de empleo
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
CL2017002170A1 (es) Desacetoxitubulisina h y análogos de esta.
GT201500190A (es) Lactamas fusionadas de arilo y heteroarilo
SV2017005405A (es) Compuestos y composiciones como inhibidores de quinasa raf
MX2021006734A (es) Metodo para tratar el cancer.
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
SV2019005822A (es) Metodos para tratar el cáncer de próstata
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
MX2019000946A (es) Administracion y dosificacion de diaminofenotiazinas.